Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade C 17.35 -0.29% -0.05
DVAX closed down 0.29 percent on Thursday, February 22, 2018, on approximately normal volume. It ran into resistance at its 50 day moving average.
16 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Down Up
See historical DVAX trend table...

Date Alert Name Type % Chg
Feb 22 50 DMA Resistance Bearish 0.00%
Feb 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Feb 22 Bollinger Band Squeeze Range Contraction 0.00%
Feb 22 Wide Bands Range Expansion 0.00%
Feb 21 50 DMA Resistance Bearish -0.29%
Feb 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -0.29%
Feb 21 Bollinger Band Squeeze Range Contraction -0.29%
Feb 21 Inside Day Range Contraction -0.29%
Feb 21 Wide Bands Range Expansion -0.29%
Feb 21 Up 3 Days in a Row Strength -0.29%

Older signals for DVAX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Is DVAX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 24.45
52 Week Low 4.0
Average Volume 1,369,260
200-Day Moving Average 15.6997
50-Day Moving Average 17.5242
20-Day Moving Average 17.122
10-Day Moving Average 17.087
Average True Range 0.9977
ADX 14.46
+DI 18.44
-DI 19.01
Chandelier Exit (Long, 3 ATRs ) 15.5069
Chandelier Exit (Short, 3 ATRs ) 18.5431
Upper Bollinger Band 18.1193
Lower Bollinger Band 16.1247
Percent B (%b) 0.61
BandWidth 11.64934
MACD Line -0.0233
MACD Signal Line -0.0998
MACD Histogram 0.0765
Fundamentals Value
Market Cap 951.45 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -7.17
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.58
Resistance 3 (R3) 18.68 18.36 18.38
Resistance 2 (R2) 18.36 18.05 18.32 18.31
Resistance 1 (R1) 17.86 17.86 17.70 17.76 18.24
Pivot Point 17.54 17.54 17.47 17.50 17.54
Support 1 (S1) 17.04 17.23 16.88 16.94 16.46
Support 2 (S2) 16.72 17.04 16.68 16.39
Support 3 (S3) 16.22 16.72 16.33
Support 4 (S4) 16.12